Page 4 - Resources Report News Today

The crew, named Full Circle Everest, has grown to seven men and two women. They live all over the country from Florida, California, New York to Colorado, and they’re no strangers to the great outdoors.

  United Oil & Gas PLC (AIM: "UOG"), the growing oil and gas company with a portfolio of production, development, exploration and appraisal assets is pleased to provide the following reserves update on the Abu Sennan concession, onshore Egypt (the "Licence").     Highlights: · Independent reserves and resources report, relevant to end 2020, by Gaffney Cline & Associates ("Independent Reserves Report") indicates material increase in reserves at ...

Egypt: United Oil and Gas announces material Uugrade to Abu Sennan reserves 14 Apr 2021 United Oil & Gas has provided a reserves update on the Abu Sennan concession, onshore Egypt. United holds a 22% working interest in the Licence, which is operated by Kuwait Energy Egypt. Highlights: Independent reserves and resources report, relevant to end 2020, by Gaffney Cline & Associates (Independent Reserves Report) indicates material increase in reserves at Abu Sennan: 24% increase in Abu Sennan Gro...

– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy – – Data to be presented during the 2021... | February 16, 2021

® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines, 1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13 th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinic...

Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma February 8, 2021 GMT ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 8, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX ® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). ...